Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
NCT04147806Phase 1Active, not recruiting
- Sponsor
- Albert Einstein College of Medicine
- Start
- Aug 2016
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Albert Einstein College of Medicine. Primary endpoint: Dose-limiting toxicity at 60 months. Started Aug 2016; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04147806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147806.